Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Masooma S Rana, Moazah Iftikhar, Yamna Jadoon, Maymona Abdelmagid, David Viswanatha, Rong He, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2024-193119

Published: 2024

Journal Articles

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients

Nadia Toumeh, Yazan Jabban, Ahmad Nanaa, Rong He, David Viswanatha, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Mehrdad Hefazi, William J. Hogan, Mithun V Shah, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2024-209413

Published: 2024

Journal Articles

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Yael Kusne, Talha Badar, Terra L. Lasho, Ludovica Marando, Abhishek A. Mangaonkar, Christy Finke, James M. Foran, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Jeanne Palmer, David Viswanatha, Mark R. Litzow, Animesh D. Pardanani, Ayalew Tefferi, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2024-202406

Published: 2024

Journal Articles

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Blood (2024) 144 (Supplement 1): 2686.

https://doi.org/10.1182/blood-2024-204334

Published: 2024

Journal Articles

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Blood (2024) 144 (Supplement 1): 440.

https://doi.org/10.1182/blood-2024-203879

Published: 2024

Journal Articles

PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations

Blood (2024) 144 (Supplement 1): 3218.

https://doi.org/10.1182/blood-2024-202688

Published: 2024

Journal Articles

Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes

Talha Badar, Terra L Lasho, Yael Kusne, Ludovica Marando, Abhishek A Mangaonkar, Christy M Finke, James M. Foran, Aref Al-Kali, Hassan Alkhateeb, Naseema Gangat, Rong He, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2023-187310

Published: 2023

Journal Articles

STAG2 and PHF6 : Comparison of 2 X-Linked Gene Mutations in Myeloid Neoplasms

Bahga Katamesh, Amrutha Mittapalli, Rong He, David Viswanatha, Dragan Jevremovic, Mehrdad Hefazi, Antoine Saliba, Abhishek A Mangaonkar, Kebede Begna, William J. Hogan, Naseema Gangat, Mrinal M. Patnaik, Mithun V Shah, Ayalew Tefferi, Mark R. Litzow, Hassan Alkhateeb, Aref Al-Kali

Blood (2023) 142 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2023-178244

Published: 2023

Journal Articles

Spectrum of clonal hematopoiesis in VEXAS syndrome

Blood (2023) 142 (3): 244–259.

https://doi.org/10.1182/blood.2022018774

Published: 2023

Includes: Supplemental data

Journal Articles

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Niamh Keane, MB, MRCP, Caleb K Stein, MS, Daniel Angelov, MSc,MB, Shulan Tian, David Viswanatha, MD, Shaji K Kumar, MD, Angela Dispenzieri, MD, Veronica Gonzalez De La Calle, MD, Kristine Misund, PhD, Robert A Kyle, MD, Michael E O'Dwyer, MD, Rafael Fonseca, MD, A. Keith Stewart, MBChB, MBA, Esteban Braggio, PhD, Yan Asmann, PhD, S. Vincent Rajkumar, MD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 393.

https://doi.org/10.1182/blood.V130.Suppl_1.393.393

Published: 2017

Journal Articles

PD-1 Expression in Chronic Lymphocytic Leukemia and Large B-Cell Richter Transformation (DLBCL-RT): A Distinguishing Feature for DLBCL-RT and Promising Surrogate Marker for Clonal Relatedness

Rong He, MD, Wei Ding, MD PhD, David Viswanatha, MD, Dong Chen, MD PhD, Min Shi, MD PhD, Daniel L. Van Dyke, PhD, Linda N Dao, MD, Sameer A. Parikh, MD, Tait D Shanafelt, MD, Timothy G. Call, MD, Stephen M Ansell, MD PhD, Jose F. Leis, MD PhD, Ming Mai, MS, Curtis A. Hanson, MD, Karen L Rech, MD

Blood (2017) 130 (Supplement 1): 4286.

https://doi.org/10.1182/blood.V130.Suppl_1.4286.4286

Published: 2017

Journal Articles

Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update

Thanh Ho, MD, Juliana Perez Botero, MD, William J Hogan, MBChB, Saad S Kenderian, MD, Naseema Gangat, MBBS, Ayalew Tefferi, MD, Roshini S Abraham, PhD, Phuong L. Nguyen, MD, Jennifer L Oliveira, MD, Rong He, MD, Dong Chen, MD PhD, David Viswanatha, MD, Vilmarie Rodriguez, MD, Shakila Khan, MD, Mrinal M Patnaik, MBBS

Blood (2016) 128 (22): 300.

https://doi.org/10.1182/blood.V128.22.300.300

Published: 2016

Journal Articles

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Wei Ding, MD PhD, Haidong Dong, MD PhD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Betsy R. Laplant, MS, Rong He, MD, Thomas E. Witzig, MD, Yi Lin, MD PhD, Asher Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Thomas M. Habermann, MD, David Viswanatha, MD, Ivana Micallef, MD, Neil E. Kay, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 834.

https://doi.org/10.1182/blood.V126.23.834.834

Published: 2015

Journal Articles

TP53 mutations and Polymorphisms in Primary Myelofibrosis,

Sania S Raza, MD, David Viswanatha, MD, Lori A Erickson, MD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Ryan A Knudson, Rhett Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3840.

https://doi.org/10.1182/blood.V118.21.3840.3840

Published: 2011

Journal Articles

Chronic myeloid leukemia with p190 BCR-ABL : prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis

Animesh Pardanani, Ayalew Tefferi, Mark R. Litzow, Clive Zent, William J. Hogan, Rebecca F. McClure, David Viswanatha

Blood (2009) 114 (16): 3502–3503.

https://doi.org/10.1182/blood-2009-07-234666

Published: 2009

Journal Articles

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

Michael J. Borowitz, Meenakshi Devidas, Stephen P. Hunger, W. Paul Bowman, Andrew J. Carroll, William L. Carroll, Stephen Linda, Paul L. Martin, D. Jeanette Pullen, David Viswanatha, Cheryl L. Willman, Naomi Winick, Bruce M. Camitta

Blood (2008) 111 (12): 5477–5485.

https://doi.org/10.1182/blood-2008-01-132837

Published: 2008

Includes: Supplemental data

Journal Articles

Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study.

Michael J. Borowitz, MD, PhD, Meenakshi Devidas, PhD, W. Paul Bowman, MD, William L. Carroll, MD, I.-Ming Chen, MD, Richard Harvey, PhD, Stephen Hunger, MD, Paul L. Martin, Jeanette Pullen, MD, David Viswanatha, MD, Cheryl L. Willman, MD, Naomi Winick, MD, Bruce Camitta, MD

Blood (2006) 108 (11): 219.

https://doi.org/10.1182/blood.V108.11.219.219

Published: 2006

Journal Articles

Association of PML-RARα Fusion mRNA Type With Pretreatment Hematologic Characteristics But Not Treatment Outcome in Acute Promyelocytic Leukemia: An Intergroup Molecular Study

Robert E. Gallagher, Cheryl L. Willman, James L. Slack, Janet W. Andersen, Yun-Ping Li, David Viswanatha, Clara D. Bloomfield, Frederick R. Appelbaum, Charles A. Schiffer, Martin S. Tallman, Peter H. Wiernik

Blood (1997) 90 (4): 1656–1663.

https://doi.org/10.1182/blood.V90.4.1656

Published: 1997

NARROW

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations

Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes

STAG2 and PHF6 : Comparison of 2 X-Linked Gene Mutations in Myeloid Neoplasms

Spectrum of clonal hematopoiesis in VEXAS syndrome

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

PD-1 Expression in Chronic Lymphocytic Leukemia and Large B-Cell Richter Transformation (DLBCL-RT): A Distinguishing Feature for DLBCL-RT and Promising Surrogate Marker for Clonal Relatedness

Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

TP53 mutations and Polymorphisms in Primary Myelofibrosis,

Chronic myeloid leukemia with p190 BCR-ABL : prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study.

Association of PML-RARα Fusion mRNA Type With Pretreatment Hematologic Characteristics But Not Treatment Outcome in Acute Promyelocytic Leukemia: An Intergroup Molecular Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only